Valence 로고
인기
로그인

관심목록에 추가

Charles River Laboratorie...

NYSE: CRL · 실시간 가격 · USD
279.19
-7.45 (-2.60%)
종가 기준: Aug 18, 2026, 3:59 PM

Charles River Laboratories International Inc. (CRL) Stock Price, Analysis & Data

-2.60%
매수호가n/a
시가총액13.45B
매출 (ttm)4B
순이익 (ttm)-238.46M
베타1.38
EPS (ttm)-4.82
P/E (ttm)n/a
선행 P/E22.01
P/B (ttm)4.69
P/S (ttm)3.33
Earnings DateNov 4, 2026
매도호가n/a
거래량595,764
평균 거래량 (20일)894,698
시가286.40
전일 종가286.64
일중 범위279.11 - 289.60
52주 범위144.26 - 289.60
애널리스트Buy
목표주가300 (7.45%)
배당n/a
배당락일n/a

CRL 소개

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research a...

[더 보기]
산업 Diagnostics & Research
섹터 Healthcare
IPO 일자 Jun 23, 2000
직원 수 18,300
상장 거래소 NYSE
티커 CRL
웹사이트 https://www.criver.com
전체 기업 정보

재무 실적

2025년 Charles River Laboratories International의 매출은 4.02B로, 전년 4.05B 대비 -0.85% 감소했습니다. 순이익은 -144.34M로, -1,501.75% 감소했습니다.

재무제표

애널리스트 전망

애널리스트 14명의 투자의견을 종합하면 CRL 주식의 평균 등급은 "Buy"입니다. 12개월 목표주가는 300로, 최근 주가 대비 7.45% 상승 여력입니다.

주가 전망

어닝 서프라이즈

Charles River Laboratories International가 Aug 5, 2026에 분기 실적을 발표했습니다:
  • 매출 $1B 예상치 하회 $0, 및 -2.72% 전년 대비 감소.
  • EPS 3.02 예상치 상회 0.28, 및 -3.21% 전년 대비 감소.

    • 다음 실적 발표

    Charles River Laboratories International Inc.의 실적 발표 예정일은 Nov 4, 2026, 장 시작 전입니다.
    애널리스트 예상 매출은 ... 업그레이드
    news image

    2일 전 · StockStory

    1 Mid-Cap Stock with Exciting Potential and 2 Facing Challenges

    Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to becoming $100 billion corporations are ripe wit...

    news image

    4일 전 · StockStory

    5 Insightful Analyst Questions From Charles River Laboratories’s Q2 Earnings Call

    Charles River Laboratories’ second quarter results were shaped by recovering biopharmaceutical demand and the impact of portfolio streamlining. Management highlighted that the rebound was most evident...

    news image

    6일 전 · Motley Fool

    Charles River Laboratories (CRL) Q2 2026 Earnings Call Transcript

    Organic revenue returned to growth as biopharmaceutical demand strengthened.

    news image

    1주 전 · Zacks

    CRAI Jumps 20% in 3 Months as Demand Broadens Across Key Practices

    CRAI's 20% three-month gain is backed by broader demand, a stronger project pipeline and higher fiscal 2026 revenue guidance, but costs remain a drag.

    news image

    1주 전 · Zacks

    International Markets and Charles River (CRL): A Deep Dive for Investors

    Explore how Charles River's (CRL) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.

    2 페이지 중 1